Did CEOs and officers buy or sell their own stock?
Open-market trades by the people who know the company best, with their own money.
Last 7 days: the stocks insiders bought and sold most
Stocks Koreans hold most · disclosed Last 7 days · open-market trades only
Bought most
Sold most
Whalegun
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Eric VenkerPresident & Immunovant CEO | Roivant SciencesROIV | Open-market sale10b5-1 plan | 09/30 | 10/02 | 200,000 sh | $36.62 | $7,324,000 | −11.1% |
Director | Roivant SciencesROIV | Open-market sale | 06/26–06/30 | 06/30 | 1,638,163 sh6 trades | $34.46avg. | $56,444,075.76 | No record |
Roivant SciencesROIV | Open-market sale | 06/26–06/30 | 06/30 | 1,438,163 sh5 trades | $34.32avg. | $49,354,075.76 | −9.5% | |
Director | Roivant SciencesROIV | Open-market sale | 06/26–06/30 | 06/30 | 1,438,163 sh5 trades | $34.32avg. | $49,354,075.76 | −9.5% |
President & CIO | Roivant SciencesROIV | Open-market sale | 06/25–06/26 | 06/29 | 1,000,000 sh2 trades | $34.11avg. | $34,105,000 | −5.1% |
Roivant SciencesROIV | Open-market sale10b5-1 plan | 06/24 | 06/26 | 200,000 sh2 trades | $33.16avg. | $6,631,267.64 | −11.0% | |
Eric VenkerPresident & Immunovant CEO | Roivant SciencesROIV | Open-market sale10b5-1 plan | 05/22 | 05/22 | 200,000 sh | $30.27 | $6,054,000 | −11.0% |
Eric VenkerPresident & Immunovant CEO | Roivant SciencesROIV | Open-market sale10b5-1 plan | 04/20 | 04/22 | 200,000 sh | $29.59 | $5,918,000 | −10.8% |
Roivant SciencesROIV | Open-market sale | 04/16 | 04/20 | 289,774 sh | $29.16 | $8,449,809.84 | −1.7% | |
Jennifer HumesChief Accounting Officer | Roivant SciencesROIV | Open-market sale | 04/08 | 04/10 | 13,538 sh | $28.37 | $384,073.06 | −13.9% |
Meghan FitzgeraldDirector | Roivant SciencesROIV | Open-market sale | 03/26 | 03/30 | 70,000 sh | $27.45 | $1,921,500 | −62.0% |
Eric VenkerPresident & Immunovant CEO | Roivant SciencesROIV | Open-market sale10b5-1 plan | 03/17 | 03/19 | 200,000 sh | $28.24 | $5,648,000 | −10.8% |
Melissa B. EpperlyDirector | Roivant SciencesROIV | Open-market sale | 03/16 | 03/18 | 41,861 sh | $28.68 | $1,200,573.48 | −72.6% |
Roivant SciencesROIV | Open-market sale10b5-1 plan | 02/19–02/23 | 02/23 | 3,000,000 sh3 trades | $27.35avg. | $82,039,460.4 | −17.9% | |
Eric VenkerPresident & Immunovant CEO | Roivant SciencesROIV | Open-market sale10b5-1 plan | 02/13 | 02/18 | 200,000 sh | $26.49 | $5,298,000 | −10.8% |
Director | Roivant SciencesROIV | Open-market sale | 02/11–02/13 | 02/13 | 1,225,784 sh5 trades | $26.64avg. | $32,658,518.16 | −7.5% |
Roivant SciencesROIV | Open-market sale | 02/11–02/13 | 02/13 | 1,225,784 sh5 trades | $26.64avg. | $32,658,518.16 | −7.5% | |
Director | Roivant SciencesROIV | Open-market sale | 02/11–02/13 | 02/13 | 1,225,784 sh5 trades | $26.64avg. | $32,658,518.16 | −7.5% |
Mayukh SukhatmePresident & CIO | Roivant SciencesROIV | Open-market sale | 02/09 | 02/11 | 339,441 sh | $26.47 | $8,985,003.27 | −1.7% |
Eric VenkerPresident & Immunovant CEO | Roivant SciencesROIV | Open-market sale10b5-1 plan | 01/12 | 01/14 | 200,000 sh | $21.92 | $4,384,000 | −10.8% |
